Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol's Belatacept Could See Approval In Second Quarter After GMP Delay

This article was originally published in The Pink Sheet Daily

Executive Summary

The kidney transplant drug Nulojix (belatacept) is finished at the plant in Puerto Rico that won't be inspection-ready until the end of the year following a August warning letter.

You may also be interested in...

Bristol/Pfizer's Apixaban Gets A Chance At The Inside Track

FDA has agreed to review the anticoagulant based on the results of the AVERROES trial, offering a potentially faster route to market.

Latest FDA Warning Letters Highlight Aseptic Processing Issues

A number of recent FDA warning letters focused on GMP issues with aseptic processing, signaling the agency’s continuing concern about contamination prevention.

When A REMS Is Not Enough: BMS Needs More Safety Data For Belatacept

FDA's "complete response" letter for kidney transplant drug does not require that Bristol-Myers Squibb do additional clinical trials, but firm must provide updates from ongoing study before approval.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts